Published By : 18 Dec 2015 | Published By : QYRESEARCH
As the 38th annual San Antonio Breast Cancer Symposium drew to an end, the meeting highlights portrayed results of two new clinical trials. The trials reveal that two new drugs available in the market are slated to reduce the chances of recurrence of breast cancer in women, who have earlier undergone treatment for the same.
Capecitabine (Xeloda), which is a chemotherapy agent improves the chances of survival of women that have HER2-negative breast cancer. The drug improves the chances of disease-free survival for women, which is not removed by presurgery chemotherapy. This was supported by studying the effects of Capecitabine after two years, the agent that was given to 901 patients as per a study conducted by Japanese researchers. Patients treated with the drug had 31% reduced risk of recurrence of the disease as compared to those who were given the placebo. On survival rate aspect, those treated with Capecitabine had 87.3% chances of disease-free survival as compared to 80.5% for those treated with the placebo.
Breast cancer therapeutics consists of a major drug class, which range from regular regimens to biological and are specifically utilized for the condition. These are HER2 inhibitors, anti-metabolites, hormone receptors, mitotic inhibitors, and aromatase inhibitors. The suitability of the drug class is dependent on the grade of cancer, which is manifested from the biopsy of the breast tissue.
Globally, breast cancer accounts for the second largest deaths that are related with cancer. Due to this, the treatment of the condition has become a major focus area for governments in both developed and developing countries. In addition, increasing awareness among the populace and introduction of premium-priced therapies by pharmaceutical manufacturers holds promise for the growth of the breast cancer therapeutics market.
The speedy approvals of breast cancer drugs have given impetus to breast cancer research, which resultantly has shifted focus towards research of new effective course for breast cancer intervention purposes.
North America is the largest market for breast cancer therapeutics due to a favorable insurance system that privileges high priced products. With the major pharmaceutical companies of the world seeking to penetrate the U.S. market, the North America market for breast cancer therapeutics will be benefitted.